|Day Low/High||73.78 / 74.94|
|52 Wk Low/High||72.21 / 111.11|
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the top-line results from three Phase 2 studies of GS-4997 (selonsertib), an investigational inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in nonalcoholic...
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
Although Gilead Sciences (GILD) shares could experience volatility leading into the U.S. presidential election, Jefferies said investors should buy the stock.
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
Don't focus on just one day of trading, Jim Cramer says.
On days like this, the money just keeps sloshing around.
Gilead (GILD) might be forced to cut prices on its HIV treatments due to heightened competition, RBC says.
The risk to Gilead Sciences' (GILD) HIV franchise from competitors' drug studies has been 'underappreciated,' says RBC Capital Markets.
Doug Kass shares his thoughts on the banks and looks back on 20 years with TheStreet.
Sales of Gilead Sciences' (GILD) hepatitis C products are still below consensus but are set to improve, Citi said.
Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
Gilead Sciences, Inc. (Nasdaq:GILD) today announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to...
Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.
Gilead (GILD) stock was down in pre-market trading on Tuesday after Leerink cut its rating on shares to 'market perform.'
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Leerink said on Monday that Gilead (GILD) could see a 'slight uplift' in its research and development strategy on partner Galapagos' (GLPG) positive drug trial results.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
Jim Cramer shares his views on why the market is hated and oil charades from the producing nations.
Citigroup analysts say recent IMS Health data show that Gilead (GILD) Hepatitis C drug sales have grown quarter-over-quarter.
Apart from the Fed, there are other factors that make investors nervous.
Gilead Sciences' (GILD) NASH liver disease pipeline is "very attractive," Gabelli said in an analyst note on Thursday.